Myelodysplastic syndromes (MDS) are a group of clonal hematological disorders characterized by ineffective hematopoiesis with morphological evidence of marrow cell dysplasia resulting in peripheral blood cytopenia. Microarray technology has permitted a refined high-throughput mapping of the transcriptional activity in the human genome. Non-coding RNAs (ncRNAs) transcribed from intronic regions of genes are involved in a number of processes related to post-transcriptional control of gene expression, and in the regulation of exon-skipping and intron retention. Characterization of ncRNAs in progenitor cells and stromal cells of MDS patients could be strategic for understanding gene expression regulation in this disease.
Methods
In this study, gene expression profiles of CD34+ cells of 4 patients with MDS of refractory anemia with ringed sideroblasts (RARS) subgroup and stromal cells of 3 patients with MDS-RARS were compared with healthy individuals using 44 k combined intron-exon oligoarrays, which included probes for exons of protein-coding genes, and for non-coding RNAs transcribed from intronic regions in either the sense or antisense strands. Real-time RT-PCR was performed to confirm the expression levels of selected transcripts.
Results
In CD34+ cells of MDS-RARS patients, 216 genes were significantly differentially expressed (q-value ≤ 0.01) in comparison to healthy individuals, of which 65 (30%) were non-coding transcripts. In stromal cells of MDS-RARS, 12 genes were significantly differentially expressed (q-value ≤ 0.05) in comparison to healthy individuals, of which 3 (25%) were non-coding transcripts.
Conclusions
These results demonstrated, for the first time, the differential ncRNA expression profile between MDS-RARS and healthy individuals, in CD34+ cells and stromal cells, suggesting that ncRNAs may play an important role during the development of myelodysplastic syndromes.
Background
Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal hematological disorders characterized by ineffective hematopoiesis with morphological evidence of marrow cell dysplasia resulting in peripheral blood cytopenia [1, 2]. Low-risk MDS are characterized by profound anemia and transfusion dependency, and a relatively low risk of progression to acute myeloid leukemia. Refractory anemia with ringed sideroblasts (RARS) is a subtype of low-risk MDS in which an excess of iron accumulates in the perinuclear mitochondria of ringed sideroblasts in the form of mitochondrial ferritin (MtF) [3–5]. However, the molecular genetic basis of RARS remains unknown.
Gene expression profile of hematopoietic progenitor cells of MDS patients demonstrates the involvement of genes related to differentiation and proliferation of progenitor cells [6–9]. Furthermore, there is increasing evidence that, in certain hematological disorders, the marrow microenvironment is abnormal, both in composition and function [10]. In MDS, the adherent layer of bone marrow stroma is defective in supporting normal myelopoiesis in vitro, presenting a poor maintenance of hematopoietic stem cells [11]. Alteration of stroma components can be implicated in the modification of the development and apoptosis of hematopoietic cells [12, 13].
The ENCODE project identified and characterized the transcriptionally active regions in 1% of the human genome, and described that the majority (63%) of transcripts was of long non-coding RNAs (ncRNAs). These transcripts resided outside GENCODE annotations, both in intronic (40.9%) and intergenic (22.6%) regions [14]. Non-coding RNAs are known to be involved in different biological processes such as cell survival and regulation of cell-cycle progression [15], transcriptional or post-transcriptional control of gene expression [16, 17], genomic imprinting [18] and biogenesis of mature RNAs through changes in the intron-exon structure of host genes [19–21]. In addition, introns have been shown to be sources of short ncRNAs such as microRNAs [22] and small nucleolar RNAs [23].
Microarray technology has permitted a refined high-throughput mapping of the transcriptional activity in the human genome [24], and has revealed different expression signatures of long intronic ncRNAs in prostate, liver and kidney [25]. In addition, sets of long intronic ncRNAs were found to be responsive to physiological stimuli such as retinoic acid [26] or androgen hormone [27]. Long ncRNAs change the interpretation of the functional basis of many diseases [28, 29]such as α-thalassemia [30], Prader-Willi syndrome [31], and cancer [32–35]. Recently, a myelopoiesis-associated regulatory intergenic non-coding RNA transcript has been described [36].
In the present study, expression profiles of CD34+ and stromal cells of MDS-RARS patients and healthy individuals were characterized with a 44 k combined intron-exon oligoarray platform, allowing the identification of protein-coding and intronic ncRNA expression signatures in MDS-RARS patients.
Methods
Patients
Bone marrow (BM) samples were collected from 4 healthy subjects and 7 MDS patients, seen at the Hematology and Hemotherapy Center, University of Campinas. All patients were diagnosed as RARS according to the French-American-British (FAB) classification and did not present chromosomal abnormalities; they received no growth factors or any further MDS treatment. Patients' characteristics are shown in Table 1. All patients and healthy subjects provided informed written consent and the National Ethical Committee Board of School of Medical Science - University of Campinas approved the study.
Table 1
Characteristics of MDS-RARS patients at the time of BM collection.
Patients (n)
Gene expression analyses for CD34+ cells
Gene expression analyses for stromal cells
Age (years)
Gender
Hb (g/dL)
ANC (×103/uL)
Platelet count (×103/uL)
BM blasts (%)
RS (%)
1
Array
None
72
F
7.2
0.95
75
2
30
2
Array, qPCR
None
78
M
8.3
1.23
136
0
58
3
Array, qPCR
qPCR
62
M
12.4
0.99
110
2
16
4
Array, qPCR
Array, qPCR
70
M
10.2
5.34
322
0
38
5
qPCR
Array, qPCR
69
F
6.7
0.51
72
0
22
6
qPCR
Array, qPCR
56
M
8.4
2.81
754
0
91
7
None
qPCR
75
M
6.3
0.75
216
0
27
Hb indicates hemoglobin; ANC, absolute neutrophil account; BM, bone marrow; and RS, ring sideroblasts
CD34+ cell and stromal cell selection
BM mononuclear cells were isolated by density-gradient centrifugation through Ficoll-Paque Plus (GE Healthcare, Uppsala, Sweden), labeled with CD34 MicroBeads, and CD34+ cells were isolated using MACS magnetic cell separation columns (Miltenyi Biotec, Mönchengladbach, Germany) according to the manufacturer's instructions. The purity of CD34+ cells was at least 92% as determined by fluorescence-activated cell sorting (FACS), using anti-CD34 antibody (Caltag Laboratories, Burlingame, CA). The mononuclear cells without CD34+, were plated onto Iscove's Dulbeccos (IMDM) (Sigma, St Louis, MO, USA) supplemented with 10% fetal bovine serum and 10% horse serum. Supernatant with non-adherent cells was removed weekly and replaced with fresh medium. When the monolayer was established (90% confluence) cells were trypsinized and plated under the same conditions. After three re-platings, a homogeneous cell population was obtained and the stromal cells were evaluated by FACS for the absence of CD34, CD45 and CD68 antigens.
RNA extraction
Total RNA was extracted with RNAspin Mini RNA Isolation Kit (GE Healthcare, Freiburg, Germany). The integrity of RNA was evaluated using Agilent 2100 Electrophoresis Bioanalyzer (Agilent Technologies, Santa Clara, CA).
Microarray experiments and data analysis
Gene expression measurements were performed using 44 k intron-exon oligoarrays that were custom-designed by the group of Verjovski-Almeida and collaborators [25] following Agilent Technologies probe specifications [37] and were printed by Agilent. The array comprises 60-mer oligonucleotide probes for 24,448 long (>500 nt) ncRNAs mapping to 6,282 unique gene loci, with genomic coordinates of the Human Genome May 2004 Assembly (hg17). Non-coding RNAs probed on the array are transcribed from either intronic regions in both the sense or the antisense strands with respect to a protein-coding gene [25] or from 1,124 intergenic regions [38]. The array also comprises 13,220 probes for the respective protein-coding genes [25]. Gene locus name annotation for intronic ncRNA is that of the protein-coding gene of the same locus; intergenic ncRNA is annotated with the name of the nearest protein-coding gene in that chromosome. All annotations were updated as of December 2009. The array design is deposited in the GEO platform under accession number GPL9193.
For each individual sample, 150 ng total RNA was amplified and labeled with Cy3 or Cy5 using the Agilent Low RNA Input Fluorescent Linear Amplification Kit PLUS, two-Color (Agilent Technologies) according to the manufacturer's recommendations. Labeled cRNA was hybridized using Gene Expression Hybridization Kit (Agilent).
Slides were washed and processed according to the Agilent Two-Color Microarray-Based Gene Expression Analysis protocol (Version 5.5) and scanned on a GenePix 4000 B scanner (Molecular Devices, Sunnyvale, CA, USA). Fluorescence intensities were extracted using Feature Extraction (FE) software (version 9.0; Agilent). A gene was considered expressed if probe intensity was significantly (p > 0.05) higher than the local background intensity, as calculated by the FE software. The software then applied local background subtraction and corrected unequal dye incorporation using the default LOWESS (locally weighted linear regression) method. We have included into further statistical analyses only those genes that were detected as expressed in all samples.
Data were normalized among the samples by quantile [39] using Spotfire DecisionSite® for Microarray Analysis (TIBCO Software Inc, Somerville, MA, USA). Genes differentially expressed between MDS-RARS and healthy individuals were identified with the Significance Analysis of Microarray (SAM) statistical approach [40] followed by a patient leave-one-out cross validation [41], which consisted in removing one sample and determining a new set of significantly altered genes using the remaining samples. This procedure was repeated for each sample, computing the statistical significance of each gene in the various leave-one-out datasets. For both CD34+ and stromal cell samples we used the following parameters: two-class unpaired responses, t-statistic, 500 permutations. We considered as significantly altered those genes that showed a minimum fold change of 1.7 and maximum false discovery rate (FDR) of 1% for CD34+ or 5% for stromal cells among all leave-one-out datasets. Less stringent parameters (5% FDR for CD34+ or 15% for stromal cells) were used for generating a list of altered genes that was uploaded to Ingenuity Pathways Analysis (IPA) software (Ingenuity® Systems, http://www.ingenuity.com) for identification of relevant altered gene networks. The software assigns statistical scores, taking into account the user's set of significant genes, network size, and the total number of molecules in Ingenuity Knowledge Base. The network score is the negative logarithm of p-value, which reflects the probability of finding the focus molecules in a given network by random chance. The identified network is then presented as a graph, indicating the molecular relationships between gene products. The raw data has been deposited in Gene Expression Omnibus (GEO) http://www.ncbi.nlm.nih.gov/geo/ database under accession number GSE18911.
Gene Ontology Annotation (GOA) database http://www.ebi.ac.uk/GOA/ was used for annotating the biological processes of proteins encoded by transcripts that were statistically significantly altered and showed at least 1.7-fold change in expression levels. Intronic non-coding RNA transcripts were annotated according to the corresponding protein-coding genes transcribed from the same loci. Functional descriptions of the genes were obtained from the Online Mendelian Inheritance in Man (OMIM) database of the National Center for Biotechnology Information (NCBI) http://www.ncbi.nlm.nih.gov/.
Quantitative real-time RT-PCR
Real-time RT-PCR was performed to confirm expression levels of expression data for selected transcripts. Reverse transcription was performed using Superscript™III Reverse Transcriptase (Invitrogen Life Technologies). Primers (Table 2) were designed using PRIMER3 software (version 0.4.0) http://frodo.wi.mit.edu/primer3/ with published sequence data from the NCBI database. For real-time PCR analysis, Power SYBR® Green PCR Master Mix (Applied Biosystems) was used, according to the manufacturer's instructions, and the reactions were run in a 7500 Real-Time PCR Systems (Applied Biosystems) for 40 cycles. Each sample measurement was performed in triplicate and a negative control, "No Template Control", was included for each primer pair. Expression of transcripts was normalized to the HPRT endogenous gene, and the relative expression was calculated as 2-ΔΔCT, where ΔΔCT is the CT value difference for each patient normalized by the average CT difference of samples from healthy subjects (ΔΔCT method) [42].
Table 2
Sequences of primers for real-time RT-PCR assays.
sense
antisense
Genes selected for validation in CD34+ cells
MY5OC
5'CGTGGCAGAAGAGGCATACA3'
5'AGCGAGCCGACACTGTCTTT3'
GCDH_ncRNA
5'aaggagctttgggtttttgt3'
5'cgccttagtgacagtctccag3'
HCK
5'GAGTTCATGGCCAAAGGAAG3'
5'GGAGGTCTCGGTGGATGTAG3'
PPIF_ncRNA
5'atcgagctttgggggtagat3'
5'agcaacagtgtagcgcaatg3'
NR4A2
5'ACTCCAACCCGGCTATGAC3'
5'CATGGAGCCAGTCAGGAGAT3'
NR4A2_ncRNA
5'cttccgggtgtctgagaaag3'
5'tttgcatgtgctaggagctg3'
NR4A3
5'TCCAGATACTGTCCCACTGACC3'
5'TCTGGATACATCAATGGAGGCT3'
NR4A3_ncRNA
5'ccgttaagcacctggttttc3'
5'aggcgctgagaattattgga3'
Genes selected for validation in stromal cells
SPINT2
5'TCTGTTTCTCTGGGAGGTAGGA3'
5'CGATCAGCGAGGAAACAACT3'
HLA-E
5'ATCGTGGGCATCATTGCT3'
5'GAGTAGCTCCCTCCTTTTCCA3'
SEMA3A
5'AGGGACCGAAAACAACGTC3'
5'CGTGGGTCCTCCTGTTTCTA3'
TBCD_ncRNA
5'TCTTGCCTGGTGAGTGTGAG3'
5'AAGGTGTTGGAAGGGAGGAG3'
SOLH_ncRNA
5'AGTCTCCAGAGTGGCATGTG3'
5'AAAGGTAGGCAGGGGAGGTA3'
Endogenous gene
HPRT
5'TCCAGCAGGTCAGCAAAGAA3'
5'GAACGTCTTGCTCGAGATGT3'
Results
Protein-coding and non-coding transcripts expression profiles in CD34+cells
CD34+ cells obtained from 4 patients with MDS-RARS (nos. 1-4; Table 1) were compared with CD34+ cells of healthy individuals using custom-designed combined intron-exon expression oligoarrays [25]. The oligoarray includes probes for protein-coding genes and for both sense and antisense strands of ncRNAs, as described in the Methods. In order to reduce the effect of individual variability, thus promoting the identification of a robust gene expression signature of MDS-RARS, Significance Analysis of Microarrays (SAM) [40] was combined with a patient leave-one-out cross validation [41]. A total of 216 significantly (q-value ≤ 0.01) differentially expressed transcripts between MDS-RARS patients and healthy individuals were identified (Figure 1), being 129 down-regulated and 87 up-regulated in MDS-RARS (Additional file 1). Interestingly, 65 differentially expressed transcripts were ncRNAs, 32 down-regulated and 33 up-regulated (Table 3).
Table 3
ncRNAs with significantly altered CD34+ expression in MDS-RARS patients in relation to healthy individuals.
Gene Locus
name1
Locus ID
ncRNA Probe Coordinates
Probe Strand
Type
Orientation relative to protein coding gene
q value2
Fold Change
Down-regulation in MDS-RARS
NEIL1
79661
chr15:73434282-73434341
+
Intronic
Sense
0.000
-4.45
BLNK
29760
chr10:97961400-97961459
-
Intronic
Sense
0.000
-3.59
KLHL5
51088
chr4:38941503-38941562
+
Intronic
Sense
0.004
-2.92
LEF1
51176
chr4:109454925-109454984
+
Intergenic
Antisense
0.001
-2.80
GABPB1
2553
chr15:48447272-48447331
+
Intergenic
Antisense
0.000
-2.55
TLE1
7088
chr9:81478431-81478490
-
Intronic
Sense
0.000
-2.30
TNFAIP3
7128
chr6:138230463-138230522
-
Intronic
Antisense
0.000
-2.21
IGSF10
285313
chr3:152637104-152637163
+
Intergenic
Sense
0.000
-2.19
CPSF6
11052
chr12:67954327-67954386
-
Intronic
Antisense
0.000
-2.16
MORN1
79906
chr1:2326963-2327014
-
Intronic
Sense
0.003
-2.15
ASAP2
8853
chr2:9299234-9299293
+
Intronic
Sense
0.003
-2.14
ST7OT1
93653
chr7:116186492-116186551
-
Intergenic
Sense
0.004
-2.13
TLE1
7088
chrX:64411696-64411755
+
Intronic
Sense
0.000
-2.12
NASP
4678
chr1:45744001-45744060
+
Intronic
Sense
0.001
-2.10
TLE1
7088
chr9:81478491-81478550
-
Intronic
Sense
0.000
-2.10
PIAS2
9063
chr18:42643244-42643303
-
Intergenic
Sense
0.000
-2.05
NUP153
9972
chr6:17815444-17815503
+
Intergenic
Sense
0.001
-2.04
ZNF76
7629
chr6:35364312-35364371
+
Intronic
Sense
0.002
-2.02
ERO1LB
56605
chr1:232705155-232705214
-
Intronic
Antisense
0.000
-1.98
CPSF6
11052
chr12:67954327-67954386
-
Intronic
Antisense
0.000
-1.97
ASXL1
171023
chr20:30410722-30410781
+
Intronic
Sense
0.001
-1.94
C5orf13
9315
chr5:111094583-111094642
+
Intronic
Antisense
0.000
-1.86
PRG4
10216
chr1:183013558-183013617
-
Intronic
Antisense
0.000
-1.86
GABPB1
2553
chr15:48448783-48448842
+
Intergenic
Antisense
0.003
-1.85
AFF1
4299
chr4:88268668-88268724
+
Intronic
Sense
0.000
-1.83
PAG1
55824
chr8:82068816-82068875
-
Intronic
Sense
0.001
-1.83
LOC441242
441242
chr7:63977853-63977912
-
Intergenic
Sense
0.003
-1.82
AASS
10157
chr7:121332812-121332871
+
Intronic
Antisense
0.001
-1.79
GCDH
2639
chr19:12871038-12871097
-
Intronic
Antisense
0.000
-1.79
SNORA71B
26776
chr20:36482692-36482751
-
Intergenic
Sense
0.001
-1.77
AFF3
3899
chr2:99698165-99698216
-
Intronic
Sense
0.004
-1.76
RBM4B
83759
chr11:66192338-66192397
+
Intronic
Sense
0.001
-1.73
Up-regulation in MDS-RARS
NR4A3
8013
chr9:99668743-99668802
+
Intronic
Sense
0.001
5.52
NR4A2
4929
chr2:157011025-157011084
-
Intronic
Sense
0.002
4.49
CCDC146
57639
chr7:76467266-76467325
-
Intronic
Antisense
0.003
4.03
MARCH1.
55016
chr4:164805948-164806007
-
Intergenic
Sense
0.002
3.77
THBS1
7057
chr15:37668391-37668450
+
Intronic
Sense
0.001
2.77
FN1
2335
chr2:216086310-216086369
+
Intronic
Antisense
0.000
2.71
RALGPS1
9649
chr9:126945696-126945747
+
Intronic
Antisense
0.000
2.70
SERPINA1
5265
chr14:93919199-93919258
+
Intronic
Antisense
0.001
2.51
EHBP1L1
254102
chr11:65104384-65104443
-
Intronic
Antisense
0.001
2.38
PPIF
10105
chr10:80781110-80781169
-
Intronic
Antisense
0.003
2.36
ANK3
288
chr10:61625808-61625867
-
Intronic
Sense
0.004
2.30
PPIF
10105
chr10:80781110-80781169
+
Intronic
Sense
0.001
2.29
ZSCAN10
84891
chr16:3082319-3082378
-
Intronic
Sense
0.004
2.24
B3GNT5
84002
chr3:184455731-184455790
+
Intronic
Sense
0.001
2.21
CYBASC3
220002
chr11:60883741-60883792
-
Intronic
Sense
0.002
2.21
NR4A2
4929
chr2:157012210-157012269
+
Intronic
Antisense
0.004
2.15
IFI30
10437
chr19:18147121-18147180
-
Intronic
Antisense
0.004
2.12
DHX38
9785
chr16:70696571-70696630
+
Intronic
Sense
0.000
2.11
FAM50A
9130
chrX:153324988-153325047
+
Intronic
Antisense
0.002
2.05
SESTD1
91404
chr2:179802621-179802672
+
Intronic
Antisense
0.000
1.91
CC2D1A
54862
chr19:13891701-13891760
-
Intronic
Antisense
0.002
1.88
SNX20
124460
chr16:49264159-49264218
-
Intronic
Sense
0.000
1.88
ICA1
3382
chr7:7932382-7932433
-
Intronic
Sense
0.000
1.86
NCOA3
8202
chr20:45714557-45714616
-
Intronic
Antisense
0.003
1.86
FRAS1
80144
chr4:79383367-79383426
+
Intronic
Sense
0.004
1.85
TMBIM6
7009
chr12:48437217-48437268
+
Intronic
Sense
0.001
1.85
CD44
960
chr11:35184235-35184294
-
Intronic
Antisense
0.000
1.83
PPP1R15A
23645
chr19:54068439-54068498
-
Intronic
Antisense
0.002
1.82
PKM2
5315
chr15:70288031-70288090
+
Intronic
Antisense
0.000
1.81
RP5-1022P6.2
56261
chr20:5491968-5492027
-
Intronic
Sense
0.002
1.81
DAGLBETA
221955
chr7:6274325-6274384
+
Intronic
Antisense
0.003
1.78
RAD51L1
5890
chr14:67951712-67951763
-
Intronic
Antisense
0.001
1.77
S100A4
6275
chr1:150330268-150330327
+
Intronic
Antisense
0.001
1.71
1Gene locus name for intronic ncRNA is that of the protein-coding gene of the same locus; intergenic ncRNA is annotated with the name of the nearest protein-coding gene in that chromosome.
2Minimum significance among all patient Leave-one-out analyses
Figure 1
Differentially expressed transcripts in CD34+cells of MDS-RARS patients and healthy individuals. The panel shows the expression matrix of 216 significantly differentially expressed genes in CD34+ cells of MDS-RARS patients compared to healthy individuals (SAM FDR <1% and fold change ≥1.7). Each row represents a single gene probe (151 protein-coding and 65 ncRNAs) and each column represents a separate CD34+ donor sample. Donor samples were clustered according to the correlation of expression profiles using the Unweighted Pair-Group Method, which resulted in two homogenous groups: MDS-RARS patients (4 columns at left) and healthy individuals (4 columns at right). Expression level of each gene is represented by the number of standard deviations above (red) or below (green) the average value for that gene across all samples. In MDS-RARS patients, a total of 87 genes were up-regulated and 129 down-regulated.
Differentially expressed protein-coding genes were related to cell adhesion, apoptosis, ion transport and regulation of transcription (Table 4). Six protein-coding genes, namely ABCB7, EBF1, IFI30, IL10RA, NR4A2 and VEGF, have been previously shown in the literature as differentially expressed in MDS-RARS [7, 43–45]. In addition, we identified a number of protein-coding transcripts not previously described as altered in MDS-RARS.
Table 4
Biological processes of genes differentially expressed in CD34+ and stromal cells from MDS-RARS patients.
1The biological processes categories were obtained from the GOA database. Genes (↑) up-regulated or (↓) down-regulated in MDS-RARS patients with respect to healthy individuals.
Ingenuity Pathways Analysis (IPA) was used for identifying enriched gene networks and functions among the differentially transcribed protein-coding genes. We identified 11 relevant networks that were significantly enriched (p-value < 0.001) with genes belonging to the MDS-RARS gene expression signature in CD34+ cells (Additional file 2). Figure 2 shows a gene network involved in hematological system development and function, humoral immune response and tissue morphology.
Figure 2
Significantly enriched gene network of protein-coding genes with altered expression in CD34+cells. Ingenuity Pathways Analysis identified that the top most significantly enriched (p < 0.001) functions of genes in this network were related to hematological system development and function, humoral immune response and tissue morphology. Gene color intensity indicates the degree of up-regulation (red) or of down-regulation (green) in CD34+ cells of MDS-RARS patients in comparison to healthy individuals. Genes in gray were not identified as differentially expressed in our experiment and white genes were either not detected as expressed in these cells or not present in our oligoarray platform. Solid lines indicate direct interaction and dashed lines indirect interactions.
Eight transcripts were chosen to validate microarray data by real-time RT-PCR. RNA extracted from CD34+ cells from 5 MDS-RARS patients (nos. 2-6; Table 1) was calculated as fold change compared with healthy controls. All transcripts were confirmed by real-time RT-PCR (Figure 3).
Figure 3
Validation of gene expression data of CD34+cells by real-time RT-PCR. Comparison of gene expression levels by real-time RT-PCR (black bars) and microarray experiments (gray bars) for eight select genes (names indicated at bottom) in CD34+ cells of MDS-RARS patients and healthy individuals. Positive and negative fold change values indicate the up- or down-regulation of expression in MDS-RARS patients in relation to the expression in healthy individuals, respectively.
Protein-coding and ncRNA transcript expression profiles in stromal cells
Stromal cells obtained from three MDS-RARS patients (nos. 4-6; Table 1) were compared with stromal cells of healthy individuals using the same custom-designed combined intron-exon expression oligoarrays and significance analysis. SAM combined with patient leave-one-out cross validation identified 12 significantly (q-value ≤ 0.05) differentially expressed genes (10 up-regulated and 2 down-regulated in stromal cells of MDS-RARS patients) (Figure 4; Additional file 3), of which 3 were ncRNAs (up-regulated in MDS-RARS patients) (Table 5). The low number of differentially expressed genes was mostly due to the high homogeneity of stromal cells from patients and donors (correlation coefficient between all donor and patient stromal samples = 0.93, contrasted to 0.9 of CD34+ cells, p = 10-5). The signature expression profile of protein-coding transcripts in MDS-RARS stromal cells revealed genes related to several biological processes, such as cell motility, DNA replication, protein amino acid phosphorylation and protein transport (Table 4).
Table 5
ncRNAs differentially expressed in stromal cells of MDS-RARS patients in comparison to healthy individuals.
Gene Locus
Name1
Locus ID
ncRNA Probe Coordinates
Probe Strand
Type
Orientation in relation to protein coding gene
q value2
Fold Change
Up-regulation in MDS-RARS
SOLH
6650
chr16:529804-529859
+
Intronic
Sense
0.000
4.40
CROCC
9696
chr1:16968607-16968658
+
Intergenic
Sense
0.038
2.40
TBCD
6904
chr17:78399392-78399451
+
Intronic
Sense
0.042
2.00
1 Gene locus name for intronic ncRNA is that of the protein-coding gene of the same locus; intergenic ncRNA is annotated with the name of the nearest protein-coding gene in that chromosome.
2 Minimum significance among all patient Leave-one-out analyses
Figure 4
Differentially expressed transcripts in stromal cells of MDS-RARS patients and healthy individuals. The panel shows the expression matrix of 12 significantly differentially expressed genes in stromal cells of MDS-RARS patients compared to healthy individuals (SAM FDR <5% and fold change ≥1.7). Each row represents a single gene (9 protein-coding genes with names in black, and 3 ncRNAs in blue) and each column represents a separate stromal donor sample. Donor samples were clustered according to the correlation of expression profiles using the Unweighted Pair-Group Method, which resulted in two homogenous groups: MDS-RARS patients (3 columns at right) and healthy individuals (4 columns at left). Expression level of each gene is represented by the number of standard deviations above (red) or below (green) the average value for that gene across all samples. In MD-RARS patients, a total of 10 genes were up-regulated and 2 down-regulated.
Ingenuity Pathways Analysis (IPA) of stromal cell genes statistically differentially expressed between MDS-RARS patients and healthy individuals (fold change ≥ 1.7; q-value ≤ 0.15 in all patient leave-one-out cross-validation analyses) identified two significantly enriched gene networks (p-value < 0.001) (Additional file 2). The most significantly enriched gene network involves genes related to cell morphology, cellular compromise, and neurological disease (Figure 5).
Figure 5
Most enriched gene network of protein-coding genes with altered expression in stromal cells. Ingenuity Pathways Analysis identified that the top most significantly enriched (p <0.001) functions of genes in this network were related to cell morphology, cellular compromise and neurological disease. Gene color intensity indicates the degree of up-regulation (red) or of down-regulation (green) in stromal cells of MDS-RARS patients in comparison to healthy individuals. Genes in gray were not identified as differentially expressed in our experiment and white genes were either not detected as expressed in these cells or not present in our oligoarray platform. Solid lines indicate direct interaction and dashed lines indirect interactions.
Four transcripts were chosen to validate microarray data by real-time RT-PCR. RNA extracted from stromal cells from 5 MDS-RARS patients (nos. 3-7; Table 1) was used for validation studies; all transcripts were confirmed by real-time RT-PCR (Figure 6).
Figure 6
Validation of gene expression data of stromal cells by real-time RT-PCR. Comparison of gene expression obtained from real-time RT-PCR (black bars) and microarray experiments (gray bars) for four select genes (names indicated at bottom) in stromal cells of MDS-RARS patients and of healthy individuals. The positive and negative fold change values indicate up- or down-regulation of expression in MDS-RARS patients in relation to the expression in healthy individuals, respectively.
Discussion
In this study, we used the 44 k intron-exon oligoarray and stringent statistical criteria to determine the protein-coding and intronic non-coding transcript expression profiles in CD34+ and stromal cells of MDS-RARS patients and healthy individuals. We herein validated the expression of a set of selected transcripts by real time RT-PCR in five MDS-RARS patients, however future confirmation in a larger group of MDS-RARS cases is warranted. Pathway analyses of differential protein-coding transcripts pointed to new genetic networks that are altered in both CD34+ and stromal cells of MDS-RARS patients (Additional file 2).
MDS are characterized by hematopoietic insufficiency associated with cytopenia, leading to severe morbidity in addition to increased risk of leukemia transformation [46]. The exact stage of CD34+ progenitor cells involved in the process of MDS and transformation to AML are still in debate. Bone marrow microenvironment contributes to regulate self-renewal, commitment, differentiation, proliferation and the dynamics of apoptosis of hematopoietic progenitors [47], and CD34+ progenitor cells are known to be severely impacted in MDS by the composition of micro environmental stimuli [48]. Detection of differentially expressed transcripts in MDS-RARS stromal cells suggests that these transcripts could contribute to maintain CD34+ cells.
Pathways analysis of the set of protein-coding transcripts altered in CD34+ cells of MDS-RARS patients revealed an important gene network related to hematological disease, including BLNK, CD19, CD72, CD81, EBF1, F5, FLT3, LY96, MPDZ and THBS1. Down-regulation in MDS-RARS of genes related to the B cell receptor signaling pathway were found in our results (BLNK, CD19 and CD72), and the low expression of several genes involved in B lymphocyte development, corroborate the hypothesis that early MDS can be defined by a B-cell progenitor defect [49].
The abnormal expression of genes encoding mitochondrial proteins involved in iron metabolism has been characterized in MDS-RARS [7, 50]. The present study found 3 different ncRNA transcripts with altered expression in the CD34+ cells of MDS-RARS patients, from gene loci of mitochondrial proteins (AASS, GCDH and PPIF) and 6 modulated mitochondrial protein-coding transcripts. In addition, corroborating our findings, the down regulation of iron transporter ABCB7 has been described in CD34+ cells of patients MDS-RARS, indicating that low ABCB7 levels would contribute to abnormal mitochondrial iron homeostasis [43]. Furthermore, genes related to heme biosynthesis pathway and transferrin trafficking (PXDN and MYO5C, respectively), were down regulated in MDS-RARS CD34+ cells. These differentially expressed genes could be related to the iron accumulation observed in mitochondria of RARS patients.
One of the mechanisms that contribute to hypercellular marrow and peripheral blood cytopenia of patients with early stage MDS is the significant increase in apoptosis of hematopoietic cells [51]. The higher expression of Fas-FasL system found in MDS plays a role in inducing MDS bone marrow apoptosis and works in both an autocrine (hematopoietic cell-hematopoietic cell interaction) or paracrine (hematopoietic cell-stromal cell interaction) pattern [52]. The protein encoded by SEMA3A (Class 3 semaphorins), a secreted member of the semaphorin family involved in axonal guidance, organogenesis, angiogenesis, and highly expressed in several tumor cells [53, 54], has recently been demonstrated to be an important determinant of leukemic cells sensitivity to Fas-mediated apoptosis signal [55]. Furthermore, Sema3A has already been described to act through different signaling pathways to control neural progenitor cell repulsion activating Erk1/2 or apoptosis process involving p38MAPK [56]. Surprisingly, SEMA3A is present in both affected networks of MDS-RARS stromal cells (see Additional file 2), suggesting participation of this gene in diverse abnormalities implicated in the modification of hematopoietic cells development and apoptosis in MDS [12, 13].
The non-coding expression profiles of CD34+ and stromal cells of MDS-RARS were clearly distinct from those obtained from CD34+ and stromal cells of healthy controls, representing 30% and 25% of the total amount of differentially expressed genes in CD34+ and stromal cells of MDS-RARS patients, respectively. Currently, evidence of the biological roles played by ncRNA have increased, especially those transcribed from partially conserved introns of protein-coding genes [57]. Recently, eosinophil granule ontogeny (EGO) has been shown to involve an ncRNA expressed during IL-5 stimulation, whose function is to regulate MBP granule protein and EDN mRNA levels [58].
Interestingly, our results showed 13 differentially expressed ncRNA transcripts in CD34+ cells of MDS-RARS patients for which there was a simultaneous change in expression of the protein-coding gene in the corresponding locus: for 7 of them both the ncRNA and the protein-coding gene were simultaneously down-regulated in MDS-RARS, 5 were up-regulated, and in one gene locus the TIN ncRNA was up-regulated whereas the protein-coding gene was down-regulated. Expression of both, protein-coding and non-coding pairs in the same locus, suggest that these intronic ncRNAs may act upon cis-regulatory factors, modulating the stability and/or processing of the corresponding protein-coding transcript, or even directly affecting the levels and/or the splicing of protein-coding isoforms [27, 59]. We found 2 altered genes of the nuclear receptor subfamily 4, group A (NR4A2 e NR4A3), known to be involved in T-cell apoptosis, brain development, and vascular disease [60], and both showed a simultaneous up-regulation of the protein-coding and the ncRNA from the same locus in MDS-RARS, suggesting that these ncRNAs could be involved in the control of protein coding expression of this gene family in MDS-RARS patients.
Conclusion
The presence of intronic ncRNA transcripts differentially expressed in CD34+ and stromal cells may shed light upon the not yet fully understood molecular mechanisms involved in the heterogeneity of myelodysplastic syndromes and suggest that ncRNAs may play a role during disease development. Characterization of those ncRNA transcripts would contribute to a better understanding of MDS-RARS, or even towards the development of biomarkers and therapeutic targets.
Declarations
Acknowledgements
The authors would like to thank Raquel S. Foglio for the English revision of the manuscript and Carolina Louzão Bigarella for her help with the preparation of the manuscript. This study was supported by the Fundação de Amparo a Pesquisa do Estado de São Paulo (FAPESP) and Conselho Nacional de Desenvolvimento Cientifico e Tecnológico (CNPq).
Authors’ Affiliations
(1)
Department of Internal Medicine, School of Medical Science, Hematology and Hemotherapy Center, University of Campinas
(2)
Departmento de Bioquimica, Instituto de Quimica, Universidade de São Paulo
References
List AF, Vardiman J, Issa JP, DeWitte TM: Myelodysplastic syndromes. Hematology Am Soc Hematol Educ Program. 2004, 297-317.Google Scholar
Mufti GJ: Pathobiology, classification, and diagnosis of myelodysplastic syndrome. Best Pract Res Clin Haematol. 2004, 17: 543-557.View ArticlePubMedGoogle Scholar
Aul C, Bowen DT, Yoshida Y: Pathogenesis, etiology and epidemiology of myelodysplastic syndromes. Haematologica. 1998, 83: 71-86.PubMedGoogle Scholar
Cazzola M, Invernizzi R, Bergamaschi G, Levi S, Corsi B, Travaglino E, Rolandi V, Biasiotto G, Drysdale J, Arosio P: Mitochondrial ferritin expression in erythroid cells from patients with sideroblastic anemia. Blood. 2003, 101: 1996-2000. 10.1182/blood-2002-07-2006.View ArticlePubMedGoogle Scholar
Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, Sanz M, Vallespi T, Hamblin T, Oscier D, et al: International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997, 89: 2079-2088.PubMedGoogle Scholar
Pradhan A, Mijovic A, Mills K, Cumber P, Westwood N, Mufti GJ, Rassool FV: Differentially expressed genes in adult familial myelodysplastic syndromes. Leukemia. 2004, 18: 449-459. 10.1038/sj.leu.2403265.View ArticlePubMedGoogle Scholar
Pellagatti A, Cazzola M, Giagounidis AA, Malcovati L, Porta MG, Killick S, Campbell LJ, Wang L, Langford CF, Fidler C, et al: Gene expression profiles of CD34+ cells in myelodysplastic syndromes: involvement of interferon-stimulated genes and correlation to FAB subtype and karyotype. Blood. 2006, 108: 337-345. 10.1182/blood-2005-12-4769.View ArticlePubMedGoogle Scholar
Hofmann WK, de Vos S, Komor M, Hoelzer D, Wachsman W, Koeffler HP: Characterization of gene expression of CD34+ cells from normal and myelodysplastic bone marrow. Blood. 2002, 100: 3553-3560. 10.1182/blood.V100.10.3553.View ArticlePubMedGoogle Scholar
Chen G, Zeng W, Miyazato A, Billings E, Maciejewski JP, Kajigaya S, Sloand EM, Young NS: Distinctive gene expression profiles of CD34 cells from patients with myelodysplastic syndrome characterized by specific chromosomal abnormalities. Blood. 2004, 104: 4210-4218. 10.1182/blood-2004-01-0103.View ArticlePubMedGoogle Scholar
Mayani H: Composition and function of the hemopoietic microenvironment in human myeloid leukemia. Leukemia. 1996, 10: 1041-1047.PubMedGoogle Scholar
Tennant GB, Walsh V, Truran LN, Edwards P, Mills KI, Burnett AK: Abnormalities of adherent layers grown from bone marrow of patients with myelodysplasia. Br J Haematol. 2000, 111: 853-862. 10.1046/j.1365-2141.2000.02467.x.PubMedGoogle Scholar
Tauro S, Hepburn MD, Bowen DT, Pippard MJ: Assessment of stromal function, and its potential contribution to deregulation of hematopoiesis in the myelodysplastic syndromes. Haematologica. 2001, 86: 1038-1045.PubMedGoogle Scholar
Flores-Figueroa E, Gutierrez-Espindola G, Montesinos JJ, Arana-Trejo RM, Mayani H: In vitro characterization of hematopoietic microenvironment cells from patients with myelodysplastic syndrome. Leuk Res. 2002, 26: 677-686. 10.1016/S0145-2126(01)00193-X.View ArticlePubMedGoogle Scholar
Birney E, Stamatoyannopoulos JA, Dutta A, Guigo R, Gingeras TR, Margulies EH, Weng Z, Snyder M, Dermitzakis ET, Thurman RE, et al: Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature. 2007, 447: 799-816. 10.1038/nature05874.View ArticlePubMedGoogle Scholar
Ginger MR, Shore AN, Contreras A, Rijnkels M, Miller J, Gonzalez-Rimbau MF, Rosen JM: A noncoding RNA is a potential marker of cell fate during mammary gland development. Proc Natl Acad Sci USA. 2006, 103: 5781-5786. 10.1073/pnas.0600745103.View ArticlePubMedPubMed CentralGoogle Scholar
Khochbin S, Lawrence JJ: An antisense RNA involved in p53 mRNA maturation in murine erythroleukemia cells induced to differentiate. EMBO J. 1989, 8: 4107-4114.PubMedPubMed CentralGoogle Scholar
Koerner MV, Pauler FM, Huang R, Barlow DP: The function of non-coding RNAs in genomic imprinting. Development. 2009, 136: 1771-1783. 10.1242/dev.030403.View ArticlePubMedPubMed CentralGoogle Scholar
Yan MD, Hong CC, Lai GM, Cheng AL, Lin YW, Chuang SE: Identification and characterization of a novel gene Saf transcribed from the opposite strand of Fas. Hum Mol Genet. 2005, 14: 1465-1474. 10.1093/hmg/ddi156.View ArticlePubMedGoogle Scholar
Krystal GW, Armstrong BC, Battey JF: N-myc mRNA forms an RNA-RNA duplex with endogenous antisense transcripts. Mol Cell Biol. 1990, 10: 4180-4191.View ArticlePubMedPubMed CentralGoogle Scholar
Brown JW, Marshall DF, Echeverria M: Intronic noncoding RNAs and splicing. Trends Plant Sci. 2008, 13: 335-342. 10.1016/j.tplants.2008.04.010.View ArticlePubMedGoogle Scholar
Du T, Zamore PD: microPrimer: the biogenesis and function of microRNA. Development. 2005, 132: 4645-4652. 10.1242/dev.02070.View ArticlePubMedGoogle Scholar
Kiss T: Small nucleolar RNAs: an abundant group of noncoding RNAs with diverse cellular functions. Cell. 2002, 109: 145-148. 10.1016/S0092-8674(02)00718-3.View ArticlePubMedGoogle Scholar
Kapranov P, Cawley SE, Drenkow J, Bekiranov S, Strausberg RL, Fodor SP, Gingeras TR: Large-scale transcriptional activity in chromosomes 21 and 22. Science. 2002, 296: 916-919. 10.1126/science.1068597.View ArticlePubMedGoogle Scholar
Nakaya HI, Amaral PP, Louro R, Lopes A, Fachel AA, Moreira YB, El-Jundi TA, da Silva AM, Reis EM, Verjovski-Almeida S: Genome mapping and expression analyses of human intronic noncoding RNAs reveal tissue-specific patterns and enrichment in genes related to regulation of transcription. Genome Biol. 2007, 8: R43-10.1186/gb-2007-8-3-r43.View ArticlePubMedPubMed CentralGoogle Scholar
Cawley S, Bekiranov S, Ng HH, Kapranov P, Sekinger EA, Kampa D, Piccolboni A, Sementchenko V, Cheng J, Williams AJ, et al: Unbiased mapping of transcription factor binding sites along human chromosomes 21 and 22 points to widespread regulation of noncoding RNAs. Cell. 2004, 116: 499-509. 10.1016/S0092-8674(04)00127-8.View ArticlePubMedGoogle Scholar
Louro R, Nakaya HI, Amaral PP, Festa F, Sogayar MC, da Silva AM, Verjovski-Almeida S, Reis EM: Androgen responsive intronic non-coding RNAs. BMC Biol. 2007, 5: 4-10.1186/1741-7007-5-4.View ArticlePubMedPubMed CentralGoogle Scholar
Szymanski M, Barciszewska MZ, Erdmann VA, Barciszewski J: A new frontier for molecular medicine: noncoding RNAs. Biochim Biophys Acta. 2005, 1756: 65-75.PubMedGoogle Scholar
Tufarelli C, Stanley JA, Garrick D, Sharpe JA, Ayyub H, Wood WG, Higgs DR: Transcription of antisense RNA leading to gene silencing and methylation as a novel cause of human genetic disease. Nat Genet. 2003, 34: 157-165. 10.1038/ng1157.View ArticlePubMedGoogle Scholar
Brito GC, Fachel AA, Vettore AL, Vignal GM, Gimba ER, Campos FS, Barcinski MA, Verjovski-Almeida S, Reis EM: Identification of protein-coding and intronic noncoding RNAs down-regulated in clear cell renal carcinoma. Mol Carcinog. 2008, 47: 757-767. 10.1002/mc.20433.View ArticlePubMedGoogle Scholar
Zhang X, Lian Z, Padden C, Gerstein MB, Rozowsky J, Snyder M, Gingeras TR, Kapranov P, Weissman SM, Newburger PE: A myelopoiesis-associated regulatory intergenic noncoding RNA transcript within the human HOXA cluster. Blood. 2009, 113: 2526-2534. 10.1182/blood-2008-06-162164.View ArticlePubMedPubMed CentralGoogle Scholar
Hughes TR, Mao M, Jones AR, Burchard J, Marton MJ, Shannon KW, Lefkowitz SM, Ziman M, Schelter JM, Meyer MR, et al: Expression profiling using microarrays fabricated by an ink-jet oligonucleotide synthesizer. Nat Biotechnol. 2001, 19: 342-347. 10.1038/86730.View ArticlePubMedGoogle Scholar
Bolstad BM, Irizarry RA, Astrand M, Speed TP: A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics. 2003, 19: 185-193. 10.1093/bioinformatics/19.2.185.View ArticlePubMedGoogle Scholar
Tusher VG, Tibshirani R, Chu G: Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA. 2001, 98: 5116-5121. 10.1073/pnas.091062498.View ArticlePubMedPubMed CentralGoogle Scholar
van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, et al: Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002, 415: 530-536. 10.1038/415530a.View ArticlePubMedGoogle Scholar
Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001, 25: 402-408. 10.1006/meth.2001.1262.View ArticlePubMedGoogle Scholar
Boultwood J, Pellagatti A, Nikpour M, Pushkaran B, Fidler C, Cattan H, Littlewood TJ, Malcovati L, Della Porta MG, Jadersten M, et al: The role of the iron transporter ABCB7 in refractory anemia with ring sideroblasts. PLoS ONE. 2008, 3: e1970-10.1371/journal.pone.0001970.View ArticlePubMedPubMed CentralGoogle Scholar
Ueda M, Ota J, Yamashita Y, Choi YL, Ohki R, Wada T, Koinuma K, Kano Y, Ozawa K, Mano H: DNA microarray analysis of stage progression mechanism in myelodysplastic syndrome. Br J Haematol. 2003, 123: 288-296. 10.1046/j.1365-2141.2003.04601.x.View ArticlePubMedGoogle Scholar
Zeng W, Miyazato A, Chen G, Kajigaya S, Young NS, Maciejewski JP: Interferon-gamma-induced gene expression in CD34 cells: identification of pathologic cytokine-specific signature profiles. Blood. 2006, 107: 167-175. 10.1182/blood-2005-05-1884.View ArticlePubMedPubMed CentralGoogle Scholar
Gupta P, Oegema TR, Brazil JJ, Dudek AZ, Slungaard A, Verfaillie CM: Structurally specific heparan sulfates support primitive human hematopoiesis by formation of a multimolecular stem cell niche. Blood. 1998, 92: 4641-4651.PubMedGoogle Scholar
Mundle SD: Lingering biologic dilemmas about the status of the progenitor cells in myelodysplasia. Arch Med Res. 2003, 34: 515-519. 10.1016/j.arcmed.2003.09.001.View ArticlePubMedGoogle Scholar
Sternberg A, Killick S, Littlewood T, Hatton C, Peniket A, Seidl T, Soneji S, Leach J, Bowen D, Chapman C, et al: Evidence for reduced B-cell progenitors in early (low-risk) myelodysplastic syndrome. Blood. 2005, 106: 2982-2991. 10.1182/blood-2005-04-1543.View ArticlePubMedGoogle Scholar
Ramirez JM, Schaad O, Durual S, Cossali D, Docquier M, Beris P, Descombes P, Matthes T: Growth differentiation factor 15 production is necessary for normal erythroid differentiation and is increased in refractory anaemia with ring-sideroblasts. Br J Haematol. 2009, 144: 251-262. 10.1111/j.1365-2141.2008.07441.x.View ArticlePubMedGoogle Scholar
Parker JE, Mufti GJ, Rasool F, Mijovic A, Devereux S, Pagliuca A: The role of apoptosis, proliferation, and the Bcl-2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS. Blood. 2000, 96: 3932-3938.PubMedGoogle Scholar
Kitagawa M, Yamaguchi S, Takahashi M, Tanizawa T, Hirokawa K, Kamiyama R: Localization of Fas and Fas ligand in bone marrow cells demonstrating myelodysplasia. Leukemia. 1998, 12: 486-492. 10.1038/sj.leu.2400980.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
